A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia

NCT ID: NCT05827991

Last Updated: 2023-04-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Androgenic alopecia (AGA) is a clinically common non cicatricial, progressive hair follicle microminiaturization disorder that begins in puberty or after puberty. The latest epidemiological survey shows that the prevalence rate of males in China is about 21.3%. In 2021, Nature published an article stating that stress hormones can inhibit hair growth by regulating hair follicle stem cells. This research conclusion provides new evidence for the impact of stress on hair growth. The trend of receiving AGA patients in the investigators' outpatient department is increasing. How to provide rapid, safe, and effective treatment for AGA patients is currently a hot topic for clinicians.
2. Studies have shown that phototherapy can effectively improve androgenic alopecia, alopecia areata, and hair loss after chemotherapy, and promote hair growth. At the same time, phototherapy can also be adjusted by adjusting the expression of reductase genes and vascular endothelial growth factor genes, as well as some endogenous epidermal growth factors, such as fibroblast growth factor and insulin-like growth factor, are also upregulated, which can stimulate hair growth.

3.1565 nm non-ablative fractional laser has the effects of inhibiting sebaceous gland secretion of oil, regulating collagen metabolism, and delaying changes in scalp collagen after hair loss. Previous studies have confirmed that 1565 nm non-ablative fractional laser therapy for alopecia areata has a good effect. Its possible mechanisms include increasing local blood flow, stimulating growth factors and cytokines during hair growth. At the same time, in order to achieve low energy, safe, and effective treatment without the need for hair cutting, the investigators had for the first time improved the 1565 nm non non-ablative fractional laser treatment tool, removing the original sapphire crystal cooling contact. This improvement can make the treatment head fully fit the scalp, and the excitation beam acts vertically on the treatment area, reducing energy attenuation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenic Alopecia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1565nm Non-ablative Fractional Laser

1565nm Non-ablative Fractional Laser

Group Type EXPERIMENTAL

1565nm Non-ablative Fractional Laser

Intervention Type DEVICE

1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.

Minoxidil

Minoxidil for external use

Group Type ACTIVE_COMPARATOR

5% minoxidil external use

Intervention Type DRUG

The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.

1565nm Non-ablative Fractional Laser combined with Minoxidil for external use

1565nm Non-ablative Fractional Laser combined with Minoxidil for external use

Group Type ACTIVE_COMPARATOR

1565nm Non-ablative Fractional Laser combined with 5% minoxidil

Intervention Type DEVICE

The two treatment mentioned above

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1565nm Non-ablative Fractional Laser

1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.

Intervention Type DEVICE

5% minoxidil external use

The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.

Intervention Type DRUG

1565nm Non-ablative Fractional Laser combined with 5% minoxidil

The two treatment mentioned above

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 18-40 years old, regardless of gender;
2. Clinical diagnosis of androgenic alopecia The diagnosis was based on the diagnostic criteria for androgenic alopecia in Clinical Dermatology, edited by Zhao Bian;
3. The patient agrees to participate in this trial and signs an informed consent form;
4. The scalp is free of bleeding, ulceration, infection, and other conditions that affect the visual field of laser surgery.

Exclusion Criteria

1. Drugs that affect hair growth, including finasteride tablets, glucocorticoids, and vasoactive drugs, have been used within 6 months before treatment;
2. Those who undergo local scalp treatment within 3 months, including topical drugs, medical cosmetic treatment, etc;
3. Combined with severe damage to important organs such as heart, liver, kidney, and brain;
4. Symptomatic alopecia caused by other diseases, such as lupus erythematosus alopecia and folliculitis alopecia;
5. Scar constitution;
6. Patients with skin malignant tumors or precancerous lesions;
7. Pregnant or nursing;
8. Recent skin infections (such as viruses and bacteria);
9. Those who cannot persist in treatment and follow-up.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xijing Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dermatology Derpartment of Xijing Hospital

Xi'an, Shaanxi, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lin Gao, PhD

Role: CONTACT

+8602984775401 ext. 029

Chen Yu, PhD

Role: CONTACT

_8613571991903 ext. 029

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gang Wang, prof

Role: primary

+8684775401

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XijingH-PF-KY20222044-F-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.